JPMorgan analyst Alexei Gogolev downgraded Enfusion to Underweight from Neutral with a price target of $9, down from $11.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ENFN: